RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders
US8673873B1 · kind B1 · utility
1Cited by
3References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 16, 2009 |
| Grant date | Mar 18, 2014 |
| Priority date | — |
| Expiry date | Nov 16, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2320/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
RNA interference is provided for inhibition of phosphodiesterase type 4 mRNA expression for treating patients with a cAMP-related ocular disorder. Phosphodiesterase type 4 mRNA targets include mRNA for 4A, 4B, 4C, and 4D phosphodiesterase isoforms.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.